New antibody targets Hard-to-Treat brain lymphoma
NCT ID NCT05485753
First seen Nov 01, 2025 · Last updated Jun 10, 2026 · Updated 36 times
Summary
This study tests a new drug called GNC-038 in people with a type of brain lymphoma that has returned or not responded to treatment. The goal is to find a safe dose and see if the drug can shrink tumors. About 7 adults will take part in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing GoBroad Boren Hospital
Beijing, Beijing Municipality, China
-
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, 100070, China
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Conditions
Explore the condition pages connected to this study.